Figure S9 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

This is a Experimental Study study.

Key Points

Combination treatment using PRMT5 and KRAS inhibitors effectively targets pancreatic cancer with specific genetic mutations.
Overrepresentation analysis indicates significant efficacy of treatments involving PRMT5i and G12Di in mutant cases.
The findings suggest a promising strategy for improving treatment outcomes in patients with MTAP-deleted KRAS-mutant pancreatic cancer.
Further research is necessary to fully understand the mechanisms of action and optimize treatment protocols.

Analysis shows overrepresentation of PRMT5 inhibitors and KRAS inhibitors, highlighting potential effectiveness for pancreatic cancer.

Figure S9 shows overrepresentation analysis of PRMT5i, G12Di, and combination treatments.

No takes yet. Share an insight, caveat, or question.

Drizyte‐Miller et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share